🔍

PPLPHARMA - Piramal Pharma

📊 NSE: PPLPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 11:01

📢 Recent Corporate Announcements

Piramal Pharma Approves FY26 Results; Re-appoints Nandini Piramal as Chairperson for 3 Years

🟡 NEUTRAL ⭐ 7/10

BOARD_MEETING 📅 28 Apr 2026, 09:23 PM

Piramal Pharma's Board has approved the audited financial results for FY26 with an unmodified auditor's opinion. Key leadership continuity was secured through the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director for three-year terms. The board also re-appointed two Independent Directors for five-year terms and appointed a new Company Secretary. These moves ensure stability in governance and strategic oversight for the upcoming years.

Audited FY26 financial results approved with an unmodified opinion from Statutory Auditors.
Nandini Piramal re-appointed as Chairperson for 3 years starting April 1, 2027.
Peter DeYoung re-appointed as Executive Director for 3 years starting October 6, 2026.
Maneesh Sharma appointed as Company Secretary and Compliance Officer effective April 29, 2026.
Registered office address changed within Mumbai effective April 30, 2026.

💡 Investors should maintain their positions as leadership continuity provides stability. Focus on the specific FY26 profit and revenue growth figures in the detailed report to assess fundamental performance.

Piramal Pharma Q4FY26: Revenue Flat at ₹2,752 Cr, FY26 EBITDA Drops 28% Amid Impairment Loss

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 28 Apr 2026, 09:19 PM

Piramal Pharma reported flat Q4FY26 revenue of ₹2,752 Cr and a 3% decline in annual revenue to ₹8,869 Cr, primarily due to inventory destocking in the CDMO segment. The company recorded a consolidated net loss of ₹326 Cr for FY26, weighed down by a ₹176 Cr impairment charge on intangible assets under development. While the CDMO business struggled with a 10% annual revenue drop, the Consumer Healthcare division grew 17% with strong e-commerce traction. Management expects a recovery in FY27 driven by improved biopharma funding and new product acquisitions like Kenalog.

FY26 EBITDA margins contracted to 13% from 17% in FY25, with absolute EBITDA falling 28% to ₹1,135 Cr.
Recognized a one-time impairment loss of ₹176 Cr in Q4FY26 due to reassessed commercial viability of certain intangible assets.
Consumer Healthcare (PCH) power brands grew 24% YoY, now contributing 52% of segment sales with e-commerce growing at 48%.
CDMO segment saw a 75% YoY increase in US biopharma funding in H2FY26, leading to a healthy pick-up in order inflows.
Net Debt remained stable at ₹4,140 Cr, while the company invested US$94Mn in Capex during FY26.

💡 Investors should monitor the recovery in the CDMO order book and margin improvement in FY27 as management expects a turnaround. The stock may face short-term pressure due to the significant annual loss and margin contraction.

Piramal Pharma Approves FY26 Results and Re-appoints Key Leadership for 3-5 Year Terms

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 28 Apr 2026, 09:12 PM

Piramal Pharma's board has approved the audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and Executive Director Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Furthermore, two independent directors were re-appointed for five-year terms, and a new Company Secretary was appointed. The board also authorized a change in the company's registered office address within Mumbai effective April 30, 2026.

Approved audited standalone and consolidated financial results for FY26 with an unmodified auditor's opinion.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Extended terms for Independent Directors Sridhar Gorthi and Peter Stevenson for 5 years each starting March 2027.
Appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026.

💡 Investors should review the detailed FY26 financial statements to assess the company's operational performance. The continuity in top management and the board is a positive sign for long-term strategic stability.

Piramal Pharma to Discuss Q4 and FY2026 Results on April 29 Earnings Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 17 Apr 2026, 02:31 PM

Piramal Pharma Limited (PPL) has scheduled its Q4 and Full-year FY2026 earnings conference call for April 29, 2026, at 9:30 AM IST. The management will discuss financial performance across its three core verticals: CDMO, Complex Hospital Generics, and Consumer Healthcare. This call is a routine but essential event for investors to understand the company's progress across its 17 global facilities and its strategic joint venture with Abbvie. The discussion will likely provide clarity on the growth trajectory of its global distribution network spanning over 100 countries.

Conference call scheduled for April 29, 2026, to review Q4 and Full-year FY2026 performance.
Management to provide updates on the 17 global development and manufacturing facilities.
Discussion will cover Piramal Pharma Solutions (CDMO), Piramal Critical Care, and Consumer Healthcare segments.
The call will include insights into the Abbvie Therapeutics India joint venture and Yapan Bio investment.

💡 Investors should monitor the earnings release on April 29 for key metrics on margin expansion and CDMO order book growth. No immediate action is required until the financial results are disclosed.

Piramal Pharma Receives US FDA EIR for Lexington Facility; Inspection Successfully Closed

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 13 Apr 2026, 10:23 AM

Piramal Pharma Limited has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Lexington, Kentucky, USA. The inspection, which was previously reported in December 2025, has been classified as Voluntary Action Indicated (VAI). This classification signifies the successful closure of the regulatory audit, ensuring the facility meets US compliance standards. The clearance is a positive development for the company's contract development and manufacturing operations in the US market.

US FDA issued an Establishment Inspection Report (EIR) for the Lexington, USA manufacturing site.
The inspection status is classified as Voluntary Action Indicated (VAI), marking a successful closure.
The audit was originally initiated and disclosed on December 11, 2025.
Successful clearance ensures uninterrupted operations and compliance for products manufactured at this facility for the US market.

💡 This regulatory clearance removes a potential overhang on the stock and validates the company's quality systems. Investors should view this as a positive signal for the company's US-based manufacturing capabilities.

Piramal Pharma Completes Acquisition of Kenalog® Branded Injectable from Bristol-Myers Squibb

🟢 POSITIVE ⭐ 8/10

M&A 📅 01 Apr 2026, 04:25 PM

Piramal Pharma's subsidiary, Piramal Critical Care B.V., has successfully completed the acquisition of the Kenalog® brand and associated products from Bristol-Myers Squibb. This strategic move is aimed at strengthening the company's Complex Hospital Generics portfolio, which is a high-margin segment. The acquisition enhances Piramal's market presence across the United States, Europe, and the Asia Pacific region. This completion follows the initial agreement announced in January 2026, marking a significant milestone in the company's inorganic growth strategy.

Successful completion of Kenalog® brand acquisition from Bristol-Myers Squibb (BMS).
Acquisition executed via Piramal Critical Care B.V., a step-down wholly owned subsidiary.
Strengthens the 'Complex Hospital Generics' portfolio across global markets.
Expands operational footprint in key geographies including the US, Europe, and Asia Pacific.
Follows through on the initial disclosure made on January 28, 2026.

💡 Investors should look for improved margins in the Critical Care segment as branded products typically offer better pricing power. Monitor upcoming quarterly earnings for the first full-quarter contribution of Kenalog® to the top line.

Piramal Pharma Assigned ESG Rating of 68.5 by SES ESG Research for FY 2024-25

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 20 Mar 2026, 08:28 PM

Piramal Pharma Limited has received an Environment, Social, and Governance (ESG) rating of 68.5 from SES ESG Research Pvt. Ltd for the financial year 2024-25. This rating was prepared voluntarily by the research firm based on publicly available data and was not commissioned by the company. ESG scores are increasingly utilized by institutional investors to assess long-term sustainability and risk management. The disclosure demonstrates the company's commitment to transparency in its non-financial reporting metrics.

SES ESG Research assigned an ESG rating of 68.5 for the FY 2024-25 period.
The rating was voluntary and not a result of a formal engagement by Piramal Pharma.
The assessment was conducted using data available in the public domain for that fiscal year.
Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should view this as a benchmark for the company's sustainability performance compared to industry peers. No immediate trading action is required as ESG ratings typically influence long-term institutional holding patterns rather than short-term price movements.

Piramal Pharma to Participate in Investec India Investor Conference on March 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 03:26 PM

Piramal Pharma Limited has scheduled an interaction with analysts and institutional investors on March 9, 2026. The company will be participating in the Investec India Promoter & Founder Conference 2026 held in Mumbai. The engagement will consist of both group and one-on-one meetings in person. This is a routine disclosure under SEBI Listing Obligations and Disclosure Requirements, 2015.

Meeting scheduled with analysts and institutional investors for March 9, 2026.
Participation in the Investec India Promoter & Founder Conference 2026 in Mumbai.
Interaction format includes both Group and One-on-one in-person meetings.
Disclosure submitted to stock exchanges on March 2, 2026, as per SEBI regulations.

💡 No immediate action is required as this is a routine investor meeting. Investors should monitor for any corporate presentations or transcripts released after the conference for updates on business strategy.

Piramal Pharma Updates Contact Details of Key Managerial Personnel for SEBI Disclosures

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Feb 2026, 05:07 PM

Piramal Pharma Limited has updated the contact details of its Key Managerial Personnel (KMP) as required under Regulation 30(5) of the SEBI Listing Regulations. The authorized personnel include Mr. Vivek Valsaraj, the Chief Financial Officer, and Ms. Pratibha Mishra, the Interim Company Secretary. These individuals are responsible for determining the materiality of events and making necessary disclosures to the stock exchanges. This is a standard administrative update to ensure regulatory compliance and transparency in corporate communications.

Compliance with Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Identification of 2 Key Managerial Personnel for determining event materiality
Mr. Vivek Valsaraj designated as Chief Financial Officer for regulatory disclosures
Ms. Pratibha Mishra designated as Interim Company Secretary for exchange communications

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor official exchange filings for material business updates.

Piramal Pharma Resumes Operations at Dahej Site Following GPCB Revocation

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 14 Feb 2026, 01:09 PM

Piramal Pharma Limited has received an interim revocation of the closure order for its Dahej manufacturing facility from the Gujarat Pollution Control Board (GPCB). The site, which was previously issued closure directions on February 4 and 12, 2026, under the Water Act, is now authorized to resume operations with immediate effect. This development follows a brief period of regulatory uncertainty regarding the plant's environmental compliance. The company is currently working with the GPCB to ensure the interim directions are made final in due course.

GPCB granted interim revocation of closure directions for the Dahej site on February 13, 2026
Company authorized to resume operations at the facility with immediate effect
Closure was originally issued under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974
Piramal Pharma is implementing measures to ensure the interim revocation is made final by the GPCB

💡 Investors should view this as a positive resolution to a potential production bottleneck; however, keep an eye on future compliance costs to ensure the revocation becomes permanent.

Piramal Pharma Digwal Facility Receives US FDA Form-483 with 4 Observations

🟡 NEUTRAL ⭐ 7/10

REGULATORY 📅 14 Feb 2026, 12:57 PM

Piramal Pharma Limited's manufacturing facility in Digwal, Telangana, underwent a US FDA inspection from February 9 to February 13, 2026. The inspection concluded with the issuance of a Form-483 containing 4 observations. These observations are procedural in nature and do not involve data integrity issues, which is a positive sign for the company's compliance culture. The US FDA has indicated a classification of Voluntary Action Indicated (VAI), suggesting that the findings are not critical to the facility's operational status.

US FDA inspection conducted at Digwal, Telangana facility from Feb 9 to Feb 13, 2026
Issuance of Form-483 with 4 observations related to procedural enhancements
No data integrity issues were reported during the inspection
Preliminary classification indicated as Voluntary Action Indicated (VAI)
Company committed to submitting a detailed response within stipulated timelines

💡 Investors should view this as a routine regulatory event with manageable outcomes given the VAI classification and lack of data integrity issues. Monitor for the final Establishment Inspection Report (EIR) to confirm the closure of these observations.

Piramal Pharma Faces Rs 1 Crore Environmental Penalty for Dahej Plant

🔴 NEGATIVE ⭐ 6/10

REGULATORY 📅 11 Feb 2026, 06:42 PM

Piramal Pharma has been hit with an interim environmental damage compensation (EDC) of Rs. 1 crore by the Gujarat Pollution Control Board (GPCB). This penalty follows a previous closure direction issued on February 4, 2026, for the company's manufacturing facility located in Dahej, Gujarat. The company is currently engaging with regulatory authorities and the courts to seek an expedited resolution to the matter. Management states that beyond the EDC and a previously disclosed bank guarantee, there is no material impact on financial or operational activities at this time.

GPCB imposed an interim environmental damage compensation of Rs. 1 crore on the Dahej site.
The penalty is linked to a closure direction issued under Section 33-A of the Water Act on February 4, 2026.
The affected facility is located at Plot No. D-2/11/A/1, GIDC Dahej, Bharuch, Gujarat.
Company is pursuing legal and regulatory channels to resolve the compliance issues and resume full operations.

💡 Investors should monitor the timeline for the lifting of the closure direction at the Dahej site, as prolonged downtime could affect production. While the Rs. 1 crore penalty is financially small, the regulatory oversight remains a point of concern for operational stability.

Piramal Pharma Partners with Blue-Zone to Recycle Waste Anesthetic Gases in Europe and Canada

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 05 Feb 2026, 11:19 PM

Piramal Critical Care (PCC), a subsidiary of Piramal Pharma, has entered a strategic collaboration with Blue-Zone Technologies to capture and recycle waste anesthetic gases. The partnership will initially deploy Blue-Zone’s Phoenix Deltasorb technology in France and Germany, pending regulatory approval. PCC will process the captured gas to produce Sevoflurane USP in Canada, creating a sustainable full-lifecycle model for essential anesthetics. This initiative aligns with global ESG trends and leverages Piramal's existing distribution network across 100+ countries.

Strategic collaboration to capture, collect, and recycle waste anesthetic gases using Blue-Zone technology.
Initial rollout targeted for France and Germany following European regulatory approval of the Phoenix Deltasorb system.
PCC will manufacture Sevoflurane USP from recycled gases at its Canadian facilities.
Leverages Piramal Pharma's global infrastructure of 17 facilities and distribution in over 100 countries.

💡 Investors should monitor the progress of regulatory approvals in Europe and the subsequent scaling of this technology. This move strengthens the company's ESG credentials and could provide a competitive edge in hospital procurement processes focused on sustainability.

Piramal Pharma Independent Director S. Ramadorai to Step Down After 5-Year Tenure

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Feb 2026, 10:43 AM

Piramal Pharma Limited has announced that Mr. Subramanian Ramadorai will complete his five-year tenure as an Independent Director on February 8, 2026. Mr. Ramadorai has opted not to seek a second term due to personal priorities, leading to his cessation from the Board effective February 9, 2026. Consequently, he will also step down from his roles as Chairman and Member of various Board Committees. The company has confirmed that there are no material reasons for his departure other than the completion of his term, and the Board has already initiated the re-constitution of relevant committees.

Mr. Subramanian Ramadorai completes a 5-year consecutive term as Independent Director on February 8, 2026.
Cessation from the Board and all committee positions is effective from February 9, 2026.
The director declined a second term to focus on personal priorities.
Board committees are being re-constituted to ensure regulatory compliance following the vacancy.
Company confirms no other material reasons for the cessation of the directorship.

💡 This is a routine management transition due to the completion of a fixed tenure; no immediate action is required. Investors should look for the announcement of a qualified successor to the Board.

Piramal Pharma Receives GPCB Closure Notice for Dahej Plant; Rs 15 Lakh Bank Guarantee Mandated

🔴 NEGATIVE ⭐ 8/10

REGULATORY 📅 04 Feb 2026, 10:15 PM

Piramal Pharma Limited has received a closure notice from the Gujarat Pollution Control Board (GPCB) for its manufacturing facility in Dahej, Gujarat. The notice, received on February 3, 2026, mandates the shutdown of industrial activities within 48 hours due to alleged violations of the Water Pollution Act. The company is also required to furnish a bank guarantee of Rs. 15,00,000. Piramal Pharma is contesting the order and is filing an urgent Writ Petition in the Gujarat High Court to seek an immediate stay on the closure.

GPCB directed closure of the Dahej site within 48 hours of notice receipt on February 3, 2026
Alleged violations involve Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974
Company must submit a bank guarantee of Rs. 15,00,000 with a one-year validity period
Piramal Pharma is seeking expedited intervention from the Gujarat High Court to reverse the order
Operational and financial impact of the potential shutdown is currently being evaluated

💡 Investors should monitor the Gujarat High Court's response to the Writ Petition as a prolonged shutdown could impact production schedules. The immediate focus should be on whether the company secures an interim stay to continue operations.

View All PPLPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total Operating Income (TOI) grew 14% YoY to INR 8,201.56 Cr in FY24. In FY25, the CDMO segment grew 15% YoY, driven by a 54% contribution from innovation-driven projects. The Piramal Consumer Healthcare (PCH) segment grew 11% YoY in FY25, with power brands growing at 20% YoY. Complex Hospital Generics (CHG) also showed strong growth, though specific percentage for the full year was not isolated from the 12% overall FY25 TOI increase.

Geographic Revenue Split

PPL is highly export-oriented, with 81% of overall revenues in FY25 derived from exports. Operations are spread across 17 manufacturing and development facilities in India, the US, the UK, and Canada, with a sourcing office in Shanghai.

Profitability Margins

PBILDT margins improved significantly from 10% in FY23 to 15% in FY24, and further to 16% in FY25. However, H1 FY26 saw a moderation to 10% due to inventory de-stocking by a major CDMO customer. PAT turned positive at INR 17.81 Cr in FY24 from a loss of INR 186.46 Cr in FY23, but 9MFY25 showed a temporary loss of INR 62.37 Cr.

EBITDA Margin

EBITDA margin stood at 16% in FY25, a 100-200 bps improvement over FY24. The company targets a sustainable 25% EBITDA margin by FY30 through operating leverage and higher capacity utilization.

Capital Expenditure

PPL is planning a capital expenditure of INR 1,500-2,000 Cr over FY25 and FY26. In FY25, the planned outflow is INR 650-750 Cr, with INR 250 Cr already spent in H1 FY25. Investments focus on capacity enhancement at Riverview (USA), Grangemouth (UK), and Aurora (Canada).

Credit Rating & Borrowing

The company holds a 'CARE AA-; Positive' rating for long-term bank facilities and 'CARE A1+' for short-term facilities. Interest outflows are projected at INR 350-450 Cr annually, with interest coverage improving to 3.07x in 9MFY25 from 2.15x in FY23.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Active Pharmaceutical Ingredients (API) and specialized chemicals for CDMO and Critical Care. For CDMO, materials are often client-specified. In Critical Care, PPL manufactures key raw materials in-house (formerly via Convergence Chemicals).

Import Sources

Approximately 20-30% of total sourcing is imported, primarily from China, Japan, and other Rest of World (RoW) markets.

Key Suppliers

For the CDMO segment, PPL procures from client-approved vendors to mitigate price volatility. Specific third-party supplier names are not disclosed in the documents.

Capacity Expansion

PPL operates 17 manufacturing facilities. Current API facilities run at 80-90% capacity, while formulations are underutilized. Expansion is underway for Antibody-Drug Conjugates (ADC) at Grangemouth, expected to be operational by the end of FY26.

Raw Material Costs

Raw material price volatility impacted margins in FY22 and FY23. CDMO contracts typically pass through costs to clients, while Critical Care in-house production helps stabilize costs. Specific cost as a % of revenue is not disclosed.

Manufacturing Efficiency

Capital intensity was 0.60x-0.65x over the last three years but is expected to improve to 0.85x in FY26 as capacity utilization increases and fixed costs are better absorbed.

Logistics & Distribution

PPL utilizes a distribution partner network in over 100 countries for Critical Care and a PAN-India network of 4 lakh distributors and 1.8 lakh chemists for the OTC segment.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

PPL aims to double revenue to USD 2 billion by FY30. Strategy includes scaling innovation-driven CDMO projects (currently 54% of segment revenue), expanding ADC capacity, increasing market share in niche generics like Sevoflurane (44% US share) and Baclofen (75% US share), and growing PCH power brands which are currently growing at 20% YoY.

Products & Services

Contract Development and Manufacturing Services (CDMO), Complex Hospital Generics (Sevoflurane, Intrathecal Baclofen), and Consumer Healthcare products (baby care, skin care, antacids).

Brand Portfolio

Little’s, Lacto Calamine, CIR, Polycrol, Tetmosol, I-pill.

New Products/Services

Expansion into Antibody-Drug Conjugates (ADC) manufacturing and a robust pipeline of early-stage molecules and Phase III projects in the CDMO segment.

Market Expansion

Focus on brownfield expansions in the United States and capacity ramp-up in the UK and Canada to serve regulated markets.

Market Share & Ranking

Maintains 44% market share for Sevoflurane in the US and 75% market share for Intrathecal Baclofen in the US.

Strategic Alliances

The Carlyle Group (via CA Alchemy Investments) holds an 18.00% stake, providing strategic and financial backing.

🌍 External Factors

Industry Trends

The industry is shifting toward innovation-led CDMO and complex generics. PPL is positioned with 54% of CDMO revenue from innovation projects and a focus on high-barrier products like ADCs.

Competitive Landscape

Operates in a competitive global CDMO and generics market; competes based on quality compliance (377+ inspections cleared) and specialized manufacturing capabilities.

Competitive Moat

Durable advantages include a zero OAI status since 2011 across all sites, high switching costs in CDMO due to regulatory filings, and dominant market shares (75%) in niche hospital generics.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical regulatory shifts and healthcare spending in the US and Europe, given 81% export revenue.

Consumer Behavior

Shift toward organized retail and e-commerce in India, where PPL has established a presence in 10,000+ modern trade outlets and online platforms.

Geopolitical Risks

Susceptible to trade barriers and import/export policy changes, particularly regarding the 20-30% of raw materials sourced from China and Japan.

⚖️ Regulatory & Governance

Industry Regulations

Strict compliance required with USFDA, UK MHRA, and PMDA. PPL has cleared 36 regulatory inspections in FY25 with zero major observations.

Environmental Compliance

Maintains a robust safety culture and ESG framework; failure to comply could lead to product recalls or site shutdowns.

Taxation Policy Impact

Not specifically disclosed; follows standard corporate tax rates in India and overseas jurisdictions.

Legal Contingencies

No major pending court cases or litigation values disclosed; maintains a clean track record with zero OAI status since 2011.

⚠️ Risk Analysis

Key Uncertainties

Regulatory risk from global agencies (USFDA) and the ability to ramp up underutilized facilities to absorb high fixed costs (INR 1,500-2,000 Cr capex).